iron deficiency anemia. Iron deficiency anemia, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Participants in this group will receive oral iron supplementation in the form of ferrous sulfate tablets. Each tablet contains three hundred and twenty-five milligr
Sponsors
Jahrom University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Women aged 18 to 45 years attending the clinics of Jahrom University of Medical Sciences Diagnosis of iron deficiency anemia based on: Hemoglobin 8–12 g/dLSerum ferritin 30 mL/min No chronic inflammatory, renal, hepatic, or malignant disease No gastrointestinal disorders affecting iron absorption (e.g., celiac disease, Crohn’s disease, intestinal resection) No history of severe allergy or intolerance to iron supplements Ability to understand study information and provide informed consent
Exclusion criteria
Exclusion criteria: Voluntary withdrawal by the participant at any time Pregnancy occurring during the study period Development of serious adverse events related to iron supplementation (e.g., severe allergic reaction or disabling gastrointestinal side effects) Non-adherence, defined as taking < 80% of the prescribed supplement Initiation or continuous use of interfering medications (e.g., antacids, proton pump inhibitors, or specific antibiotics) A final diagnosis other than iron deficiency anemia (e.g., anemia of chronic disease, thalassemia) Hospitalization or any clinical deterioration that prevents continuation of participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Blood Hemoglobin Concentration. Timepoint: Measurement of blood hemoglobin concentration at baseline (before initiation of the intervention) and eight weeks after initiation of the intervention. Method of measurement: Measurement of blood hemoglobin concentration using peripheral blood sampling and analysis with an automated blood cell counter in a university-affiliated clinical laboratory.;Severity of Gastrointestinal Adverse Effects Related to Iron Supplementation. Timepoint: Assessment of the severity of gastrointestinal adverse effects at baseline (before initiation of the intervention) and then weekly until the end of the eighth week of the intervention. Method of measurement: Assessment of the severity of gastrointestinal adverse effects including nausea, vomiting, abdominal pain, constipation, and diarrhea using a ten-point visual analogue scale completed by the participants. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adherence to Oral Iron Supplementation. Timepoint: Assessment of adherence to oral iron supplementation weekly during the intervention period and at the end of the eighth week. Method of measurement: Assessment of adherence to treatment based on pill count and participant self-report recorded in weekly follow-up forms.;Change in Serum Ferritin Concentration. Timepoint: Measurement of serum ferritin concentration at baseline (before initiation of the intervention) and eight weeks after initiation of the intervention. Method of measurement: Measurement of serum ferritin concentration using blood samples and the immunoassay method in a university-affiliated clinical laboratory.;Serum Hepcidin Level. Timepoint: Measurement of serum hepcidin level at baseline (before initiation of the intervention) and eight weeks after initiation of the intervention. Method of measurement: Measurement of serum hepcidin level using blood samples and the enzyme-linked immunosorbent assay (ELISA) method in a university-affiliated clinical laboratory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Ali Rostamipour
Jahrom University of Medical Sciences
Outcome results
None listed